Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders

Table 4 Logistic multiple regression results on the association between lack of sustained viral response, bipolar disorder (for which lower frequency of sustained viral response was observed in the present study), and known risk factors of non-response to antiviral treatment in the studied cohort (n = 14272)

Parameter	OR	95%CI	P value
Bipolar disorder	3.52	0.76-16.34	0.109
Male sex	1.93	1.51-2.45	< 0.0001
Obesity (BMI > 30 kg/m2)	1.08	0.82-1.43	0.579
GT3	3.26	2.50-4.27	< 0.0001
Cirrhosis	2.55	2.01-3.22	< 0.0001
HIV-coinfection	1.37	0.88-2.13	0.165
HBV-coinfection	0.85	0.61-1.18	0.323
History of HCV-treatment failure	1.46	1.14-1.87	0.003
ASV+DCV	4.97	2.60-9.55	< 0.0001
SOF/VEL	0.86	0.61-1.20	0.371
SOF/VEL+RBV	2.37	1.34-4.17	0.003

BMI: Body mass index; GT: Genotype; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ASV: Asunaprevir; DCV: Daclatasvir; SOF: Sofosbuvir; VEL: Velpatasvir; RBV: Ribavirin; OR: Odds ratio; CI: Confidence interval.